5-Hidroksitriptofan
 | |
 | |
| Nazivi | |
|---|---|
| IUPAC naziv (2S)-2-amino-3-(5-hidroksi-1H-indol-3-il)propanoinska kiselina | |
| Identifikacija | |
| |
3D model (Jmol) |
|
| ChEBI |
|
| DrugBank |
|
| ECHA InfoCard | 100.022.193 |
| KEGG[1] |
|
SMILES
| |
| Svojstva | |
| C11H12N2O3 | |
| Molarna masa | 220,2246 |
| Farmakologija | |
| Načini upotrebe | Oralno; Oralno; |
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa). | |
 Y verifikuj (šta je  Y Н ?) | |
| Reference infokutije | |
5-Hidroksitriptofan (5-HTP, oksitriptan) aminokiselina je i hemijski prekurzor koji se prirodno javlja. On je metabolički intermedijer biosinteze neurotransmitera serotonina i melatonina iz triptofana.
5-HTP je u prodaji na slobodno u znatnom broju zemalja kao prehrambeni dodatak. On se koristi kao antidepresant, supresant apetita, i sredstvo za spavanje. Neka od njegovih prodajnih imena su: Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, i Triptum. Nekoliko dvostruko slepih placebom kontrolisanih kliničkih ispitivanja je pokazalo da je efektivan za tretiranje depresije. Dodatne studije, većih razmera su neophodno da bi njegova efikasnost u potpunosti potvrdila.[2][3][4][5][6][7][8][9][9][10][11][12][13][14][15]
Reference
- ^ Joanne Wixon; Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast. 17 (1): 48—55. doi:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ^ Turner EH, Blackwell AD: 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypotheses. 2005;65(1):138-44. PMID 15893130
- ^ Shaw K, Turner J, Del Mar C: Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;(1):CD003198. PMID 11869656
- ^ Rahman MK, Nagatsu T, Sakurai T, Hori S, Abe M, Matsuda M: Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats. Jpn J Pharmacol. 1982 Oct;32(5):803-11. PMID 6983619
- ^ Nakatani Y, Sato-Suzuki I, Tsujino N, Nakasato A, Seki Y, Fumoto M, Arita H: Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. Eur J Neurosci. 2008 May;27(9): 2466-72. PMID 18445233
- ^ Bouchard S, Roberge AG: Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat. Can J Biochem. 1979 Jul;57(7):1014-8. PMID 39668
- ^ Amamoto T, Sarai K: On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression. Hiroshima J Med Sci. 1976 Sep;25(2-3):135-40. PMID 1088369
- ^ Magnussen I, Jensen TS, Rand JH, Van Woert MH: Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man. Acta Pharmacol Toxicol (Copenh). 1981 Sep;49(3):184-9. PMID 6175178
- ^ а б Birdsall TC: 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998 Aug;3(4):271-80. PMID 9727088
- ^ Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK: Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980 Oct 2;303(14):782-7. PMID 6997735
- ^ Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V: Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun;18(3):201-9. PMID 2193835
- ^ Trouillas P, Serratrice G, Laplane D, Rascol A, Augustin P, Barroche G, Clanet M, Degos CF, Desnuelle C, Dumas R, et al.: Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol. 1995 May;52(5):456-60. PMID 7733839
- ^ De Benedittis G, Massei R: Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. J Neurosurg Sci. 1985 Jul-Sep;29(3):239-48. PMID 3913752
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMID 21059682.
- ^ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (Nucleic Acids Res) (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. 36 (Database issue): D901—6. PMID 18048412. CS1 одржавање: Вишеструка имена: списак аутора (веза)
Spoljašnje veze
Portal Hemija
- 5-Hydroxytryptophan
- p
- r
- u
Antagonisti i/ili inhibitori | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| |||||||||
Triciklični i tetraciklični antidepresivi (TCA/TeCA) | |||||
|---|---|---|---|---|---|
| |||||
Inhibitori monoamin oksidaze (MAOI) | |||||||
|---|---|---|---|---|---|---|---|
| |||||||
Alnespiron • Aripiprazol • Befiradol • Buspiron • Eptapiron • Flesinoksan • Flibanserin • Gepiron • Ipsapiron • Oksaflozan • Tandospiron • Vilazodon • Zalospiron |
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
5-Hidroksitriptofan na srodnim projektima Vikipedije:
Mediji na Ostavi
Podaci na Vikipodacima
